Decoy Therapeutics Advances Pan-Coronavirus Antiviral Toward FDA IND Filing
I'm PortAI, I can summarize articles.
Decoy Therapeutics Inc. is advancing its peptide conjugate therapeutics pipeline, focusing on countermeasures for emerging pathogens. The company plans to file an Investigational New Drug (IND) application with the U.S. FDA for a pan-coronavirus antiviral within the next 12 months. Other programs include a broad-acting antiviral for flu, COVID-19, and RSV, as well as a peptide drug conjugate for GI cancers. The intranasal pan-coronavirus fusion inhibitor will validate Decoy’s new manufacturing network. Future research and development results will be presented.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments